FindMyKOL

Paul Celano, MD

Basic profile

Greater Baltimore Medical Center

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionBaltimore, MD · NortheastSpecialtyMedical OncologyFocusOncology
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH funding1990–1993

Paul Celano is an Oncology physician affiliated with Greater Baltimore Medical Center. OpenAlex indexes 41 publications with 5,866 citations (h-index 23).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
41publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

5,866citations

Citations across these publications.

23h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
36companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 1990–1993

Federally funded research awards.

View funding ↓

Industry payments

36 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Merck & Co.
    Program year20252 paymentsResearch
    $26,996
  • Pfizer
    Program year20251 paymentResearch
    $3,000
  • SpringWorks Therapeutics
    Program year202512 paymentsResearch
    $2,390
All 64 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    68.5%
    Integrin Receptor Antagonist37.6%
    Vedolizumab100%
    Part B, office-administered≥11 patients
    PD-1 inhibitor30.1%
    Pembrolizumab100%
    Part B, office-administered≥15 patients

    + 6 more classes in this area

  • Metabolism & gastrointestinal

    14%
    Other antiemetics12.5%
    Fosaprepitant100%
    Part B, office-administered≥14 patients
    Serotonin-3 Receptor Antagonist1.4%
    Palonosetron hcl100%
    Part B, office-administered≥21 patients

    + 1 more class in this area

  • Musculoskeletal

    13%
    RANK Ligand Inhibitor12.2%
    Denosumab100%
    Part B, office-administered≥20 patients
    Bisphosphonate0.8%
    Zoledronic acid100%
    Part B, office-administered≥85 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 1990–1993 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”